Side-by-side · Research reference

TeriparatidevsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED10/62 cited

BPhase 3HUMAN-REVIEWED9/42 cited

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

Teriparatide

VIP

Primary target

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

Yes — exogenous VIP acts as physiological agonist

Origin

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

Teriparatide

VIP

Standard dose (osteoporosis)

20 mcg / day

FDA-approved regimen for severe osteoporosis.

—

Frequency

Once daily

Intermittent administration preserves anabolic effect.

—

Maximum duration

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

—

Hypoparathyroidism dose

20 mcg / day

Used off-label for chronic hypoparathyroidism.

—

Evidence basis

RCT / FDA-approved

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Pelvic fragility fractures

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

—

Route

Subcutaneous (thigh or abdomen)

—

Timing

Morning or evening (flexible)

—

Storage

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

—

Pharmacogenetics

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

—

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

Reconstitution

—

Lyophilized powder reconstituted with sterile diluent per protocol

Half-life

—

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

03Metabolic / Fat Loss Evidence

Parameter

Teriparatide

VIP

Fat loss application

None — teriparatide is a bone anabolic agent without direct lipolytic activity

—

04Side Effects & Safety

Parameter

Teriparatide

VIP

Hypercalcemia

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

—

Orthostatic hypotension

Dizziness, lightheadedness within hours of injection

—

Nausea

Common, usually mild and transient

—

Leg cramps / Arthralgia

Musculoskeletal pain reported in clinical trials

—

Hypercalciuria

Increased urinary calcium excretion; monitor for nephrolithiasis risk

—

Osteosarcoma (black box warning)

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

—

Injection site reaction

Erythema, bruising, pain (uncommon)

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

GI symptoms

—

Nausea, diarrhea (VIP is endogenous GI peptide)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

Teriparatide

VIP

1. Device preparation

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Injection site

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Injection technique

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Monitoring

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.

6. Calcium and vitamin D supplementation

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.

—